This opinion will explore agitation in AD by describing the molecular basis of agitation and how therapeutic agents THC and melatonin reduce agitation by targeting neuroinflammation, CB1r imbalance, and neurotransmitter imbalances. Here, CNR1 is linked to Alzheimer disease.